Teva Pharmaceutical Industries (TEVA) News Today $20.05 -0.16 (-0.79%) Closing price 03:59 PM EasternExtended Trading$20.11 +0.06 (+0.32%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TEVA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Teva Pharmaceutical Industries (NYSE:TEVA) Receives "Sell (D-)" Rating from Weiss Ratings4 hours ago | marketbeat.comZacks Research Issues Positive Forecast for TEVA EarningsOctober 8 at 8:13 AM | marketbeat.comDAVENPORT & Co LLC Decreases Holdings in Teva Pharmaceutical Industries Ltd. $TEVAOctober 8 at 4:16 AM | marketbeat.comTeva Pharmaceutical: Turnaround Driven By Huge Pipeline UpsideOctober 7 at 5:01 AM | seekingalpha.comBillionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight QuartersOctober 6 at 3:06 AM | fool.comTeva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Public Employees Retirement System of OhioOctober 5, 2025 | marketbeat.comJPMorgan Chase & Co. Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock PriceOctober 5, 2025 | americanbankingnews.comJP Morgan Maintains Teva Pharmaceutical Industries Limited - Depositary Receipt (TEVA) Overweight RecommendationOctober 4, 2025 | msn.comTruist Financial Corp Reduces Stake in Teva Pharmaceutical Industries Ltd. $TEVAOctober 4, 2025 | marketbeat.comTeva (TEVA) Is Up 9.2% After New Schizophrenia Drug Data and Innovation Shift - What’s ChangedOctober 3, 2025 | finance.yahoo.comTeva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $26.00October 3, 2025 | marketbeat.comGreenwood Capital Associates LLC Decreases Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVAOctober 3, 2025 | marketbeat.comUBS Maintains its Buy Rating on Teva Pharmaceutical Industries Limited (TEVA); Raises Its Price Target to $26.00October 1, 2025 | insidermonkey.comTruist Securities Reaffirms Its Buy Rating for Teva Pharmaceutical Industries Limited (TEVA)October 1, 2025 | insidermonkey.comTeva Pharmaceutical Industries Target of Unusually High Options Trading (NYSE:TEVA)September 30, 2025 | marketbeat.comUnpacking the Latest Options Trading Trends in Teva Pharmaceutical IndusSeptember 30, 2025 | benzinga.comTeva Pharmaceutical Industries (NYSE:TEVA) Trading Up 4.3% - Should You Buy?September 30, 2025 | marketbeat.comBourgeon Capital Management LLC Acquires 363,252 Shares of Teva Pharmaceutical Industries Ltd. $TEVASeptember 30, 2025 | marketbeat.comBig Pharma braces for the next price cutSeptember 26, 2025 | proactiveinvestors.comTL1A Binder Market Set to Expand by 2034 with Key Players Such as Merck, Roche, Teva Pharmaceuticals, Sanofi, and Others Driving Multi-Indication Advancements | DelveInsightSeptember 25, 2025 | finance.yahoo.comTeva Releases Q3 2025 Aide MemoireSeptember 25, 2025 | financialpost.comFTeva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025September 25, 2025 | financialpost.comFTeva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025September 25, 2025 | globenewswire.comTeva Releases Q3 2025 Aide MemoireSeptember 25, 2025 | globenewswire.comTeva Pharmaceuticals: Pipeline Momentum Signals New Era For InvestorsSeptember 25, 2025 | seekingalpha.comUBS Group Increases Teva Pharmaceutical Industries (NYSE:TEVA) Price Target to $26.00September 24, 2025 | marketbeat.comTeva Pharmaceutical Industries Limited (TEVA) Presents at Bank of America Global Healthcare Conference 2025 TranscriptSeptember 24, 2025 | seekingalpha.comTeva Pharmaceutical Industries Limited (TEVA) Discusses On Olanzapine LAI (TEV-'749) Phase 3 SOLARIS Data Presentation (Transcript)September 23, 2025 | seekingalpha.comTeva Pharmaceutical Industries Limited - Special CallSeptember 22, 2025 | seekingalpha.comOlanzapine LAI (TEV-'749) Phase 3 SOLARIS Data PresentationSeptember 22, 2025 | seekingalpha.comTeva preesents 10 posters from its schizophrenia medicines portfolioSeptember 22, 2025 | msn.comTeva announces presentation of data from survey of patients taking AUSTEDO XRSeptember 22, 2025 | msn.comTeva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by IFM Investors Pty LtdSeptember 22, 2025 | marketbeat.comTeva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Voya Investment Management LLCSeptember 21, 2025 | marketbeat.comTeva Pharmaceutical Industries Ltd: Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High SatisfactionSeptember 21, 2025 | finanznachrichten.deTeva Pharmaceutical Industries Shares Positive Patient Survey Results for AUSTEDO XR® in Tardive Dyskinesia TreatmentSeptember 20, 2025 | quiverquant.comQNew Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS ObservedSeptember 20, 2025 | globenewswire.comAssenagon Asset Management S.A. Buys 2,462,064 Shares of Teva Pharmaceutical Industries Ltd. $TEVASeptember 20, 2025 | marketbeat.comTeva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Consensus Rating of "Buy" by AnalystsSeptember 20, 2025 | marketbeat.comGateway Investment Advisers LLC Increases Stake in Teva Pharmaceutical Industries Ltd. $TEVASeptember 18, 2025 | marketbeat.comTeva Pharmaceutical Industries (NYSE:TEVA) Shares Down 5.1% - Should You Sell?September 17, 2025 | marketbeat.comMedincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 PresentationSeptember 17, 2025 | businesswire.comStrs Ohio Makes New Investment in Teva Pharmaceutical Industries Ltd. $TEVASeptember 17, 2025 | marketbeat.comTeva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych ...September 16, 2025 | markets.businessinsider.comTeva Pharmaceutical Industries (TEVA) Attains FDA’s Fast Track Designation for EmrusolminSeptember 16, 2025 | finance.yahoo.comTeva Pharmaceutical Industries Ltd. to Present Phase 3 SOLARIS Trial Data at 2025 Psych Congress Annual MeetingSeptember 16, 2025 | quiverquant.comQTeva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meetingSeptember 16, 2025 | globenewswire.comTeva Pharmaceutical Industries Limited (TEVA)’s Emrusolmin Gains FDA Fast Track for Multiple System AtrophySeptember 16, 2025 | insidermonkey.comLingohr Asset Management GmbH Has $302,000 Stock Position in Teva Pharmaceutical Industries Ltd. $TEVASeptember 16, 2025 | marketbeat.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $54.37 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVASeptember 16, 2025 | marketbeat.com Get Teva Pharmaceutical Industries News Delivered to You Automatically Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TEVA Media Mentions By Week TEVA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TEVA News Sentiment▼0.960.77▲Average Medical News Sentiment TEVA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TEVA Articles This Week▼1815▲TEVA Articles Average Week Get the Latest News and Ratings for TEVA and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Teva Pharmaceutical Industries and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies GSK News ARGX News TAK News ONC News INSM News BNTX News GMAB News SMMT News ASND News VTRS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:TEVA) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Teva Pharmaceutical Industries With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
